Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jieyu No.2 granule is a traditional Chinese medicine (TCM) formulation developed by the Shanghai Municipal Hospital of Traditional Chinese Medicine for the treatment of mild to moderate depressive disorders. The medication is prepared as a granule for oral administration and is designed to alleviate symptoms of depression through the synergistic effects of its constituent herbal extracts. Clinical evaluation, including the randomized controlled trial ChiCTR2000038608, has focused on its efficacy in reducing Hamilton Depression Scale (HAM-D) scores in adult patients compared to placebo. As a hospital-developed preparation, it represents an integration of traditional herbal knowledge with modern clinical trial methodology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jieyu No.2 granule.